Patricia R. Hebert, Ph.D. Associate Professor of Internal Medicine

B.S., University of Florida, 1968; M.S., University of Florida, 1975; Ph.D. in Epidemiology, University of Texas School of Public Health, Houston, Texas; Joined Yale faculty, 2000.

Research Interests: Risk factors for cardiovascular disease and, in particular, genetic causes of cardiovascular disease; Overviews of treatment responses and adverse effects associated with drug therapies for cardiovascular disease; Methodologic issues related to studies of interactions and disease risks.

I have a clinical interest in genetic contributions to risk of cardiovascular disease. Our collaborative group is actively involved in examining genetic interactions between the renin-angiotensin and fibrinolytic systems. We are also interested in effects of polymorphisms in treatment responses to cardiovascular drugs in widespread use. We have, in addition, explored alternative analytic methods to address power issues frequently encountered in studies involving genetic interactions.

I have also performed a number of overviews of treatment responses to drugs used for prevention and treatment of cardiovascular diseases, including statins and stroke and aspirin in the primary prevention of cardiovascular disease. Most recently, with other investigators at Yale, we have examined the risks of adverse outcomes associated with beta blocker therapy.


Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs: risk of stroke and total mortality. JAMA. 1997; 278:313-321.

Hebert PR, Ridker PM, Fuster V, Hennekens CH. Antithrombotic agents in the secondary and primary prevention of cardiovascular disease in high and usual risk individuals. In Verstraete M, Fuster V, Topol EJ (eds). Cardiovascular Thromobosis: Thrombocardiology and Thromboneurology. Lippincott-Raven, Philadelphia 1998.

Cook NR, Hebert PR, Manson JE, Buring JE, Hennekens CH. Self-selected post trial aspirin use and subsequent cardiovascular disease and mortality in the Physicians’ Health Study. Arch Intern Med. 2000; 160:921-928.

Hebert PR, Pfeffer MA, Hennekens CH. Use of statins and aspirin to reduce risks of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2002; 7:77-80.

Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtin JP, Krumholz HM. Beta blocker therapy and symptoms of depression, fatigue and sexual dysfunction. JAMA 2002; 288:351-357.

Ko, DT, Hebert PR, Coffey CS, Foody JM, Curtis JP, Sedrakyan A, Krumholz HM. Adverse effects of beta blockers for heart failure patients: a quantitative review of the randomized trials (submitted).

Copyright © 2000, Yale University, New Haven, Connecticut, USA.
All rights reserved. Comments or suggestions to site editor.
Certifying authority:

Last modified: Friday, 12-Dec-2003 08:59:20 EST (PL).